News
Lilly trial shows weight loss with experimental pill
Digest more
Novo Nordisk is “no longer the elephant in the room,” analysts led by Kerry Holford said as they upgraded the stock to Buy ...
Eli Lilly (LLY) stock is in focus as its popular GLP-1 med Mounjaro hits main goals in a Phase 3 trial for children and ...
A class-action lawsuit accuses CVS Caremark of denying medically necessary treatments by stopping coverage of Zepbound, Eli ...
Two New York residents have filed a lawsuit against CVS after the company’s pharmacy benefit manager, Caremark, denied coverage for Zepbound in favor of Wegovy. The plaintiffs — Dennis Larkin of ...
14don MSN
Where Will Eli Lilly Be in 3 Years?
Eli Lilly ( LLY -2.24%) stock has soared in the triple digits over the past three years thanks to one particular product line ...
Novo Nordisk (NVO) shares rose 6% premarket on Thursday after a real-world study showed its diabetes drug Ozempic ...
Eli Lilly said its experimental oral GLP-1 drug orforglipron outperformed Novo Nordisk’s oral semaglutide in a head-to-head phase 3 trial. In a 52-week study involving 1,698 adults with Type 2 ...
The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative ...
The U.S. Food and Drug Administration issued warning letters to Eli Lilly , Novo Nordisk and telehealth firm Hims & Hers ...
In letters to Eli Lilly and Novo Nordisk, the FDA accused the companies of downplaying the risks of their GLP-1 weight loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback